UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Position in Guardant Health, Inc. (NASDAQ:GH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 30.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,612,777 shares of the company's stock after selling 1,131,260 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 2.11% of Guardant Health worth $79,820,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in Guardant Health by 13.5% during the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after buying an additional 391 shares in the last quarter. Arizona State Retirement System lifted its holdings in Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after buying an additional 403 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in Guardant Health during the 4th quarter worth approximately $26,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GH. The Goldman Sachs Group raised their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a report on Friday, February 21st. Piper Sandler restated an "overweight" rating and issued a $60.00 price objective (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Stifel Nicolaus raised their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Finally, Guggenheim restated a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Twenty-one equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $52.32.

Insider Activity

In related news, CEO Amirali Talasaz sold 106,784 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the sale, the chief executive officer now owns 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 107,132 shares of company stock valued at $5,248,393 over the last quarter. Corporate insiders own 6.10% of the company's stock.

Guardant Health Stock Performance

NASDAQ GH traded up $1.92 during trading on Friday, reaching $40.47. The company's stock had a trading volume of 699,799 shares, compared to its average volume of 2,127,056. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of -11.38 and a beta of 1.49. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $52.92. The business's fifty day moving average price is $42.79 and its 200-day moving average price is $40.35.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business's quarterly revenue was up 20.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.